Case Study: Next Generation Engineering Platforms to Enhance Adoptive NK Cell Therapies
Time: 4:30 pm
day: Conference Day One
Details:
- Improving the specificity, persistence, and antitumour activity of NK cells by engineering them with CAR
- Precision genome editing of NK or CAR NK cells using CRISPR-cas9 technology to enhance their potency and circumvent tumour induced immunosuppression
- Arming NK cells or CAR NK cells with antibodies to improve their cytolytic activity and allow multi-targeting
